OBJECTIVE: To evaluate the clinical and therapeutic efficacy of 2% @entity3402 vaginal cream in pregnant @entity1 heavily colonized with @entity1892 ( @entity1892 ). STUDY DESIGN: A prospective, clinical trial in which carriers of @entity1892 were randomized to receive topical intravaginal @entity3402 or oral @entity115 . @entity1 : We randomized 105 pregnant @entity1 : 55 received 2% @entity3402 vaginal cream (100 mg/day for 7 days) and 50 oral @entity115 (2 g/day for 7 days). INTERVENTIONS: @entity1 were treated during pregnancy, none of them received intrapartum chemoprophylaxis. On the other hand, all the neonates, within 24 hours from delivery, were studied from the microbiological point of view, carrying out auricolar, nasal, oropharyngeal and umbilical cultures. RELIEFS: The eradication of the microorganism was evaluated by performing a vaginal culture after 6 weeks from the beginning of antibiotic therapy. RESULTS: The eradication rate of the microorganism was significantly higher in @entity1 treated with topical @entity3402 compared with the group receiving oral @entity115 (71% versus 36%; p < 0.05). The neonatal outcome was similar in the two groups in terms of gestational age at delivery and mean birthweight. None of the neonates was admitted to the neonatal intensive care unit and no cases of @entity295 were recorded. CONCLUSIONS: From our experience we can conclude that, during pregnancy, a treatment with topical intravaginal @entity3402 may be useful in the eradication of @entity1892 .

[Streptococcus group B and pregnancy: the therapeutic role of topical intravaginal XXXX ].

@entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'PATIENTS'] @entity295 :: ('MESH:D018805', 'Disease') :: ['neonatal sepsis'] @entity115 :: ('MESH:D000658', 'Chemical') :: ['amoxicillin'] @entity1892 :: ('MESH:D016393', 'Disease') :: ['GBS', 'group B streptococci'] @entity3402 :: ('MESH:D002981', 'Chemical') :: ['clindamycin']
@entity3402 :: (MESH:D002981,Chemical) :: ['clindamycin']
